

# Financial Tear Sheet

## Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

## Stock Information

### PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$6.61</b>
Change (%)	<b>▲ 0.24 (3.77%)</b>
Volume	566,310
52 Week Low	\$4.50
Market Cap	\$213,401,219
Rolling EPS	-3.64
PE Ratio	N/A
Shares Outstanding	32,284,602

Data as of 01/16/19 4:00 p.m. ET



## Recent Paratek Pharmaceuticals News & Events

01/02/19 - 4:01 p.m.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

There are currently no events scheduled.

12/03/18 - 4:01 p.m.

Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030

11/27/18 - 8:01 a.m.

Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a

## Common Subset of Complicated Urinary Tract Infections

---

## SEC Filings

Filing Date	Form
01/04/19	8-K
12/26/18	4
12/14/18	4
12/14/18	4

## Management

Michael F. Bigham	Chief Executive Officer and Chairman of the Board
Evan Loh, M.D.	President, Chief Operating Officer and Chief Medical Officer
Douglas W. Pagán	Chief Financial Officer
Adam Woodrow	Chief Commercial Officer
William Haskel	General Counsel and Corporate Secretary
Randy Brenner	Senior Vice President - Regulatory, Quality and Technical Operations
Regina Paglia	Senior Vice President - Human Resources
Evan Tzanis	Chief Development Officer

Jason Burdette	Vice President - Technical Operations
Jeanne Jew	Senior Vice President - Business Development
Raj Padmanabhan	Vice President - Information Technology
Susan Perkins, J.D.	Vice President - Intellectual Property
Christine R. Coyne, MBA	Vice President - Marketing
Sarah Higgins	Vice President - Controller
Paul McGovern, M.D.	Vice President - Clinical and Medical Affairs
Steve Sandor, MBA, J.D.	Vice President - Market Access and Trade
Judith N. Steenbergen, PhD	Vice President, Medical Strategy and Communications

Data provided by Nasdaq. Minimum 15 minutes delayed.